InvestorsHub Logo
Followers 21
Posts 1996
Boards Moderated 0
Alias Born 11/26/2014

Re: None

Thursday, 02/17/2022 7:51:00 AM

Thursday, February 17, 2022 7:51:00 AM

Post# of 4159
July 30, 2020, Of the 4 patients that were removed from Study II, the clinical protocol in effect at the time stated in the patient withdrawal criteria that “Patients found to have at Day 90 new T1 high-grade disease, with or without CIS” and “Patients found to have unchanged or worsening CIS at 3 months” will be removed from Study II.
Of the 4 patients removed from the Study, they presented with “unchanged CIS at 3 months”.

This was an oversight on behalf of the Company and the clinical protocol has since been updated to remove these two specific patient withdrawal criteria, maintaining the key patient withdrawal criteria of NMIBC progression,
______________________________________

Looks like 8 of the First 12 from phase 2 are up for the 2nd treatment at full dose!

67% CR @ 18 months. Patients removed after 24 moths from the study.

Only the doc knows about the 24 mo results from the phase 2 but.... but he diald back the first dozen to lower dose levels....

Before 409 was on the market it was 410 but it was so strong they had to dial it back. just sayin.


TLTFF GOLD STANDARD FOR NMIBC NONRESPONSE

___________________________________________

Looks like 8 of the First 12 from phase 2 are up for the 2nd treatment at full dose!

67% CR @ 18 months. Patients removed after 24 moths from the study.

Only the doc knows about the 24 mo results from the phase 2 but.... but he diald back the first dozen to lower dose levels....

Before 409 was on the market it was 410 but it was so strong they had to dial it back. just sayin.


TLTFF GOLD STANDARD FOR NMIBC NONRESPONSE
________________________________________________

Picked up more Good CR from 1 of 2.
12 -4=8-2=6 patients to get second dose full.
maybe we get 3 of 6 back from our first dozen. yep yep

Note: There are 2 patients that received an unoptimized primary Study II Treatment and were diagnosed as non-responsive; however, they then received an optimized maintenance Study II Treatment. Analyzing these 2 patients, 1 remained non-responsive and 1 achieved a CR at 270 days and PR at 360 and 450 days, respectively.

As of November 29, 2021





JMO, maybe, maybe not.